Arvaya Healthcare Limited (formerly Bijoy Hans Limited) reported a return to profitability on a consolidated basis for the first quarter ended June 30, 2026, driven by a sharp expansion in revenue. The company posted a consolidated net profit after tax of ₹53.23 lakh, a significant improvement from the net loss of ₹25.29 lakh recorded in the corresponding quarter of FY25.

Consolidated revenue from operations more than tripled to ₹2,990.67 lakh in Q1FY27, up from ₹911.33 lakh in Q1FY26. This top-line growth outpaced the preceding quarter’s revenue of ₹911.33 lakh, indicating accelerated business activity in the current period. The Board of Directors approved the unaudited financial results in a meeting held on August 12, 2026.

Consolidated vs Standalone Performance

While the consolidated group turned profitable, the standalone operations continued to incur losses. The standalone entity reported a net loss after tax of ₹88.57 lakh for the quarter, compared to a loss of ₹119.73 lakh in Q1FY25. Standalone revenue was negligible at ₹10 lakh, suggesting that the majority of the operational activity and profitability is generated through subsidiaries or associates included in the consolidated figures.

The basic earnings per share (EPS) for the consolidated entity stood at ₹0.08, compared to a negative EPS of ₹0.53 in the previous year. Paid-up equity share capital remained unchanged at ₹4,802.19 lakh.

What the Numbers Show

The divergence between consolidated and standalone results highlights the company's reliance on its group structure for current profitability. With standalone revenue at just ₹10 lakh against consolidated revenue of nearly ₹3,000 lakh, the parent entity contributes minimally to the top line. The substantial increase in consolidated revenue suggests either new business acquisitions, increased volume in subsidiary operations, or a change in consolidation scope, although the specific drivers were not detailed in the filing.

Arvaya Healthcare board approved the incorporation of a wholly-owned subsidiary to enter the insurance broking sector. The decision was taken at a meeting held on August 12, 2026, marking a strategic expansion into financial services adjacent to its healthcare operations.

The proposed entity will be incorporated in India and will operate as a related party to the listed company. Arvaya Healthcare will retain 100% shareholding in the new venture. The specific name of the subsidiary is pending approval from relevant authorities, and the cost of subscription remains undecided.

Regulatory Approvals Required

The subsidiary must obtain regulatory clearance before commencing operations. The company stated it will apply to the Insurance Regulatory Development Authority of India (IRDAI) for approval to conduct insurance broking business. This regulatory step is mandatory under current Indian insurance laws.

Disclosure Compliance

The company issued the intimation pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Kaushal Shah, Managing Director, signed the filing on behalf of the company.